Robert Citron
CFO @ Molecular Detection
Robert Citron is a Series A investor at Molecular Detection focused on FinTech and Crowdfunding. Robbie Citron brings to OurCrowd over 25 years of experience in financial management, including over a decade of working with start-ups through his role as Partner and CFO of Jerusalem Global Ventures, a leading Israeli venture capital fund. He also serves as consulting CFO for several independent Israeli biotech and medical start-ups, mostrecently with Izun Pharmaceuticals and Molecular Detection, Inc. Earlier in his career, Robbie was Financial Controller and Company Secretary of the Israeli branch of Hanson PLC and worked as a public accountant with PricewaterhouseCoopers in Israel and BDO Stoy Hayward in London. He is a Certified Public Accountant in Israel and a Fellow of the Institute of Chartered Accounts in England & Wales. Robbie received an honors degree in accounting and finance from the London School of Economics and Political Science and sets aside part of his spare time to work with several Jerusalem-based charitable institutions.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Robert Citron invests in
Stages Robert Citron invests in
Countries Robert Citron invests in
Investment Focus
Industry
- FinTech 1 (100%)
- Crowdfunding 1 (100%)
- Venture Capital 1 (100%)
- Angel Investment 1 (100%)
- Funding Platform 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
OurCrowd
|
OurCrowd is a venture investing platform that enables institutions and individuals to invest and engage in emerging companies. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global 'crowd' gains access to VC-level investment opportunities. | Series A / Feb 06, 2013 |
About Molecular Detection
Molecular Detection Inc. (MDI) is developing and commercializing a portfolio of "sample-to-answer" Detect-Readyâ„¢ molecular diagnostic tests for the rapid detection of infectious diseases. The company is preparing to launch its first product, the Detect-Ready assay for the rapid detection of methicillin-resistant Staphylococcus aureus(MRSA), a growing problem among hospitals and other health facilities around the globe.
Molecular Detection Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Robert Citron
CFO
|
|||
David Wilson
Vice President, Commercial Operations, Europe
|
|||
Fredi Kleinman
Director of Production
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Robert Citron invest in?
Robert Citron invests primarily in FinTech, Crowdfunding and Venture Capital startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Robert Citron last invest?
The most recent investment recorded for Robert Citron closed in Feb 2013. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
